Ivo Buchhalter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7546728/publications.pdf

Version: 2024-02-01

28 papers	5,780 citations	304368 22 h-index	500791 28 g-index
30 all docs	30 docs citations	30 times ranked	10560 citing authors

#	Article	IF	Citations
1	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	0.8	106
2	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	7.7	125
3	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
4	Framework for quality assessment of whole genome cancer sequences. Nature Communications, 2020, 11, 5040.	5.8	5
5	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	13.7	94
6	Butler enables rapid cloud-based analysis of thousands of human genomes. Nature Biotechnology, 2020, 38, 288-292.	9.4	11
7	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
8	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	2.3	95
9	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	2.3	85
10	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
11	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
12	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	3.9	17
13	EML4â€ALK fusion variant V3 is a highâ€risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ nonâ€small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	2.3	93
14	Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology, 2018, 50, 327-332.	0.3	27
15	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	1.5	20
16	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.3	21
17	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	5.1	151
18	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	5.1	268

#	Article	IF	Citations
19	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathologica, 2017, 134, 155-158.	3.9	26
20	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. Journal of Experimental Medicine, 2017, 214, 2073-2088.	4.2	30
21	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
22	Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases. OncoImmunology, 2016, 5, e1213931.	2.1	14
23	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	13.7	318
24	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	3.9	203
25	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
26	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
27	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	5.8	266
28	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520